This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Updated annually, our Private Markets Review offers the best of our research and insight into private equity, private real estate, and other private markets. Explore the findings from our most recent report and scroll for past years’ reports.
Cardi B has been one of the most prominent music artist to date. She’s known for many things, including her famous catch phrase: “Okurrr.” However, Cardi B wants to pursue intellectual property protection for the phrase “Okurr,” such as trademark protection. But she may face some obstacles. What are the obstacles In the office action, […].
With everyone talking about Coronavirus, don't forget the Interagency Statement on Pandemic Planning. [link] When it was issued, banks were supposed to develop a written policy to deal with H1N1 flu, SARs, MERs, and other potential pandemics. You should already have such a policy. Expect to be asked about it at your next regulatory examination, so be prepared.
CAR T-Cell therapy, a new biologic therapy, is taking off. As companies continue to develop this new and promising therapy, patent litigation inevitably follows. CAR T-Cell therapy can be thought of as turbo-charging a patient’s own T-cells to treat cancer. At a high level, CAR T-Cell therapy works as follows: (1) a patient’s own T-cells are extracted and shipped to a laboratory, (2) scientists genetically engineer the T-cells to express a chimeric antigen receptor (CAR) that will re
Software is complex, which makes threats to the software supply chain more real every day. 64% of organizations have been impacted by a software supply chain attack and 60% of data breaches are due to unpatched software vulnerabilities. In the U.S. alone, cyber losses totaled $10.3 billion in 2022. All of these stats beg the question, “Do you know what’s in your software?
Approaching my first blogging anniversary, I am honored that Feedspot.com has named this one of the world's top 75 Bank Blogs. I'm glad to be in the top 75, and I hope, with your help as a blog follower, or even better if you link to this blog, to vault rapidly up the ladder. Let's quickly segue to my favorite topic these days, cybersecurity.
I feel silly writing this blog, but once again, I find myself facing a mess because a bank gave legal advice to a customer. This time, a friend and her three siblings own a Delaware limited liability company that owns four rental properties in New Jersey. Her mother, the manager of the LLC, died last September. When my friend tried to change the signature on the LLC account, the platform officer told her she had to file the LLC in New Jersey and sign a new beneficial ownership certification.
Buried in a 2020 spending bill passed in December 2019 is a provision that amends the definition of “Biological Product” in the Biologics Price Competition and Innovation Act of 2009 (BPCIA) and thereby expands the products that will be regulated as biologic medicines and litigated under the BPCIA. The BPCIA defined “Biological Product” as “a virus, therapeutic serum, toxin, antitoxin, vaccine, blood, blood component or derivative, allergenic product, protein (excep
Buried in a 2020 spending bill passed in December 2019 is a provision that amends the definition of “Biological Product” in the Biologics Price Competition and Innovation Act of 2009 (BPCIA) and thereby expands the products that will be regulated as biologic medicines and litigated under the BPCIA. The BPCIA defined “Biological Product” as “a virus, therapeutic serum, toxin, antitoxin, vaccine, blood, blood component or derivative, allergenic product, protein (excep
We organize all of the trending information in your field so you don't have to. Join 9,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content